AFL Stock Offers 44 Years of Dividend Growth and Solid Income

Insurance stocks can be a volatile game—with income from floods, wildfires, interest, and claims increases. Then there's Aflac NYSE: AFL.

This money-saving insurance policy that allows investors to sleep at night generates consistent income, increases its dividends, returns stock, and enjoys long-term appreciation. In fact, Aflac has raised its dividend for 44 consecutive years, and after a strong first quarter in 2026, the company shows no signs of stopping.

The question is whether the stock's well-earned reputation has already been baked into the price, or whether there is still enough upside for new buyers. For retail investors who prefer loyalty over excitement, Aflac may be a duck for income.

How Aflac Makes Its Money

Most investors know the Columbus, Georgia-based insurance company best from its TV commercials featuring the cured duck. Few can understand how a company makes money.

The company sells life insurance and disability insurance, but is better known as a supplemental insurance provider, meaning it sells policies that pay cash directly to policyholders when they experience a covered illness or injury.

The business model is simple. If a cancer diagnosis or accident forces someone out of work, Aflac cash benefits help cover everyday expenses, such as mortgage payments, groceries, or utility bills, that cannot be covered by standard health insurance.

That niche has made Aflac a force in two distinct markets. In the United States, the company sells its additional programs primarily through employers, building long-term relationships with businesses.

In Japan, where Aflac has operated since 1974, the company has a dominant position in cancer insurance and medical capital products. Indeed, part of Aflac's business comes from Japan, where brand recognition competes with major domestic insurance companies.

Profits Remain Strong Under Titles

While Aflac's first-quarter earnings may seem like a surprise, beneath the numbers is a stronger picture.

On a constant basis, earnings came in at $1 billion, or $1.98 per diluted share. That compares to just $29 million, or 5 cents per diluted share, in the same period last year, when the company lost a net investment of $963 million, or $1.76 per diluted share. In contrast, the first three months of this year brought in investment gains of $49 million, or 10 cents per share.

Adjusted earnings, without return on investment, tell a modest but strong story. Adjusted net income came in at $901 million for the quarter, actually down $906 million from a year ago. Adjusted earnings per diluted share rose 5.4% to $1.75, thanks largely to a reduction in share price as the company continues to buy back its own stock.

Japan and the US Continue to Grow

Its two flagship markets also tell a very different story. In Japan, pre-tax adjusted earnings rose 5.1% in dollar terms to $759 million, on premiums earned totaling $1.57 billion. In domestic yen terms, premiums received decreased by 4% YOY. At the same time, new annualized premium sales for the quarter increased by 25.5%, driven by the latest health-related products designed for younger Japanese consumers.

In the United States, written premiums grew 3.5% to $1.56 billion, while adjusted pre-tax income increased 1.4% to $363 million. Again, these are not exciting numbers, but the steady increase that investors expect.

For all of 2025, for example, Aflac reported adjusted earnings of $4 billion, or $7.49 per diluted share, an estimated decline from $4.1 billion in 2024 in absolute terms. But with the stock buyback, it was still an improvement per share.

Shareholder Returns Are Always Important

Buybacks and dividends are important to Aflac with no signs of slowing down. The company set its quarterly dividend at 61 cents per share in the first quarter after rising 5.2%. It also said it returned $1.3 billion to shareholders during the quarter alone, including $1 billion in share repurchases and $315 million in dividends.

This kind of consistency has kept the stock reasonably priced. Shares are up more than 10% in the past 12 months, and are up nearly 5% this year. In five years, the stock doubled. With a P/E ratio of around 13 and a dividend yield of just over 2%, the company's stable performance and payouts are evident.

As such, Wall Street analysts are broadly divided on the stock, with an overall recommendation of a Hold rating, indicating the current price may already reflect a large portion of the company's quality. In fact, with 12 analysts following the stock, the 12-month target price of $112.27 is basically a downside from current levels. Six analysts recommend Hold, four recommend Buy, and two recommend Sell.

Aflac Is Always a Reliable Income Stock

Aflac is clearly not a stock for investors chasing rapid growth. It's a stock for investors who want to own a piece of a long-lasting, well-managed business that reliably generates cash, increases its dividends, and slowly lowers its share price.

The method is simple. Aflac is one of the most reliable income-generating stocks in the insurance sector of the financial sector, competing against rivals such as MetLife. NYSE: MET and the Colonial Life unit of the Unum Group NYSE: UNM.

There will be some volatility in earnings with currency fluctuations and investment results, and the stock will respond. But for investors who want stability over surprise, the duck is still worth considering. The biggest risk is not that the company stumbles. That investors pay the full value of the business is well understood by the market.

Before you consider Aflac, you'll want to hear this.

MarketBeat tracks Wall Street's top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aflac wasn't on the list.

Although Aflac currently has a hold rating among analysts, senior analysts believe these five stocks are better buys.

View Five Stocks Here

Want to capitalize on the electric car mega-trend? Click the link to see our list of which EV stocks are showing the most long-term potential.

Get This Free Report